LearnGlossaryMarketStocksSuperinvestorsSign in

CSTL

Castle Biosciences, Inc.

Healthcare · $1.1B market cap

Verdict

We can't put a fair value on CSTL right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-4.7% a year✗
Sales growth45.0% a year✓
Free cash flow growth34.9% a year✓
Return on invested capital-7.3%✗

Follow CSTL

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: no open-market purchases, 3 sales worth $195K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

Oelschlager Kristen M

Chief Operating Officer · 2026-09-01

Sold

$7K

Oelschlager Kristen M

Chief Operating Officer · 2026-09-01

Sold

$132K

Juvenal Tobin W

Chief Commercial Officer · 2026-08-31

Sold

$57K

Other filings

Oelschlager Kristen M

Chief Operating Officer · 2026-09-01

Option exercise

$14K

About Castle Biosciences, Inc.

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with…

Medical - Diagnostics & Research

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works